Avanir, Actavis Inc. neurology news

Avanir and Actavis settled a 2011 suit alleging Actavis' ANDA for a generic version of Nuedexta dextromethorphan/quinidine to treat pseudobulbar affect (PBA) infringes Avanir's U.S. Patent Nos. 7,659,282 and RE38,115. Under the settlement, Actavis received rights to begin selling its generic version on July 30, 2026, or earlier under undisclosed criteria. PBA is characterized by involuntary episodes of laughing and/or crying.

The '282 patent, which expires in 2026, covers compositions comprising of dextromethorphan in combination with quinidine for treatment of neurological disorders. The '115 patent, which expires in 2016, covers the use of dextromethorphan with quinidine for treating intractable conditions. ...